Management of asymptomatic primary tumours in stage IV colorectal cancer: Review of outcomes

Table 1 Study characteristics

Ref.	Years data collected	Country	Type of study	Total n	% of group receiving chemo	Predominant chemotherapy regime	Targeted agent use
2 arms: PTR vs PC				(PTR n/PC n)	(PTR/PC)
Yun et al[18] (2014)	2000-2008	South Korea	Retrospective, propensity-score matched cohort, single centre	416 (218/198)	66/100	Doublet	ND
Matsumoto et al[19] (2014)	2005-2011	Japan	Retrospective, single centre	88 (41/47)	85/100	Doublet	Approx 50% received targeted agent
Ahmed et al[42] (2014) Subgroup	1992-2005	Canada	Retrospective, multicentre	834	100/100	ND	< 2%
Cetin et al[22] (2013)	2006-2010	Turkey	Retrospective, multi centre	99 (53/46)	100/100	Doublet	100% received bevacizumab
Boselli et al[15] (2013)	2010-2011	Italy	Retrospective, single centre	48 (17/31)	65/100	Doublet	> 50% received bevacizumab 1st line
Seo et al[20] (2010)	2001-2008	South Korea	Retrospective, single centre	227 (144/83)	100/100	Doublet	5%-10% received bevacizumab; 5%-10% received EGFR monoclonal antibody
Galizia et al[25] (2008)	1995-2005	Italy	Retrospective, single centre	65 (42/23)	100/100	Singlet	Nil
Benoist et al[26] (2005)	1997-2002	France	Retrospective, case matched, single centre	59 (32/27)	94/100	Singlet	Nil
Michel et al[21] (2004)	1996-1999	France	Retrospective, single centre	54 (31/23)	97/100	Doublet	Nil
Ruo et al[43] (2003)	1996-1999	United States	Retrospective, single centre	230 (127/103)	ND/83	Singlet	Nil
Scoggins et al[44] (1999)	1985-1997	United States	Retrospective, single centre	89 (66/23)	ND/100	Singlet	Nil
Single arm: Primary chemotherapy				n	% group receiving chemo
Yun et al[23] (2014)	2000-2011	South Korea	Retrospective, single centre	259	100	Doublet	ND
McCahill et al[16] (2012)	2006-2009	United States	Prospective Phase 2	86	100	Doublet	100% received bevacizumab
Clements et al[45] (2009)	2003-2006	United Kingdom	Retrospective, single centre	37	92	Doublet	ND
Bajwa et al[27] (2009)	1999-2005	United Kingdom	Retrospective, single centre	67	100	Doublet	ND
Poultsides et al[24] (2009)	2000-2006	United States	Retrospective, single centre	233	100	Doublet	48% received bevacizumab 1st line
Muratore et al[46] (2007)	2000-2004	Italy	Prospective, single centre	35	100	Doublet	Nil
Sarela et al[47] (2001)	1997-2000	United Kingdom	Retrospective and prospective, single centre	24	87	Singlet	Nil
Single arm: Primary tumour resection				n	% group receiving chemo
Maeda et al[28] (2013)	2001-2009	Japan	Retrospective, single centre	94	85	Doublet	33% received targeted agent
Matsuda et al[17] (2012)	1998-2007	Japan	Retrospective, single centre	40	74	Doublet	ND

PTR: Primary tumour resection; PC: Primary chemotherapy; ND: Not documented.